To include your compound in the COVID-19 Resource Center, submit it here.

Safinamide: Completed Phase III enrollment

Merck's Merck Serono S.A. division completed enrollment of 549 PD patients with motor fluctuations in

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE